At CMSC 2023, the associate professor of neurological sciences at the University of Vermont in Burlington talked about data surrounding multiple sclerosis diagnosis and misdiagnosis, suggesting the need for the development of diagnostic biomarkers. [WATCH TIME: 5 minutes]
At CMSC 2023, the professor of neurology at Barts and The London School of Medicine and Dentistry discussed the emerging paradigm shift in understanding multiple sclerosis (MS) as a smoldering disease and the potential role of Epstein Barr Virus in causing MS. [WATCH TIME: 6 minutes]
Neurology News Network for the week ending June 2, 2023. [WATCH TIME: 3 minutes]
At CMSC 2023, the neuromuscular and movement disorders speech-language pathologist at Orlando Health discussed the importance of early intervention in speech and communication therapy, as well as the challenges faced in getting patients to seek therapy at the time of diagnosis. [WATCH TIME: 5 minutes]
The adjunct instructor at the UCSF Weill Institute for Neurosciences provided perspective on the next steps in research for potential wearable devices focused on treating issues of multiple sclerosis. [WATCH TIME: 2 minutes]
The professor of molecular neuroscience at the Edmond and Lily Safra Center for Brain Sciences discussed the premise behind a study of RNA-sequencing data to better understand the reasons why females suffer accelerated dementia. [WATCH TIME: 9 minutes]
Experts in neurology provide insight on challenges that arise with the use of generic DMTs in RRMS treatment, such as cost to the patient.
Ahmed Zayed Obeidat MD, PhD; Ravi Dukkipati, MD; and Gabriel Pardo, MD, FAAN, comment on the use of generic DMTs in the treatment of RRMS, highlighting efficacy and safety data as well as level of equivalence to brand name treatments.
The clinical professor in the department of neurology at the University of California, San Francisco, emphasized the need to restrict trichloroethylene availability and the challenges in studying environmental factors associated with Parkinson disease. [WATCH TIME: 4 minutes]
In recognition of World MS Day, the health and rehabilitation psychologist at the Rowan Center for Behavioral Medicine discussed types of interventions for managing cognitive changes in patients with multiple sclerosis. [WATCH TIME: 5 minutes]
The medical director of SleepMed in South Carolina discussed the need for more overall awareness of poor sleep and the risk factors associated with worsened heart health. [WATCH TIME: 3 minutes]
The clinical professor in the Department of Neurology at the University of California, San Francisco, talked about the association between contaminated water and Parkinson disease. [WATCH TIME: 6 minutes]
Neurology News Network for the week ending May 27, 2023. [WATCH TIME: 3 minutes]
The director of the Memory & Cognitive Disorders Clinic at Hoag Neuroscience Institute provided perspective on the difficulties with testing agents for Parkinson disease psychosis, and the future outlook of treating the symptom. [WATCH TIME: 4 minutes]
The director of vascular neurology at NYU Langone Hospital in Brooklyn discussed the high prevalence of common risk factors for stroke, emphasizing the importance of early detection and management for prevention. [WATCH TIME: 4 minutes]
The associate professor at the University of Colorado highlighted the limitations of standard care visits in collecting crucial data from pediatric multiple sclerosis centers. [WATCH TIME: 3 minutes]
The head of CRCSEP and coordinator of the Neurosciences Research Unit at Paris City University discussed the positive results of teriflunomide in treating radiologically isolated syndrome, a preclinical stage of multiple sclerosis. [WATCH TIME: 4 minutes]
Expert neurologists discuss treatment options for a patient with comorbid autoimmune diseases, relapsing/remitting multiple sclerosis, and psoriasis.
Ravi Dukkipati, MD, and Gabriel Pardo, MD, FAAN, review the use of rituximab and other disease-modifying therapies in a patient with an established diagnosis of relapsing/remitting multiple sclerosis.
Neurology experts discuss the unmet needs in narcolepsy treatment and share clinical pearls from their experiences.
Experts discuss sodium oxybate and antidepressants for treatment of cataplexy.
Experts discuss the efficacy and safety profile of solriamfetol for the treatment of narcolepsy.
The director of the James J. and Joan A. Gardner Family Center discussed data from the phase 3 BouNDless trial assessing a continuous, subcutaneous levodopa/carbidopa delivery system for patients with Parkinson disease experiencing motor fluctuations. [WATCH TIME: 3 minutes]
The director of the Memory & Cognitive Disorders Clinic at Hoag Neuroscience Institute discussed the future of treating Parkinson disease psychosis, and potential ways to lower risk of poor long-term outcomes. [WATCH TIME: 3 minutes]
Episode 34 of the AUPN Leadership Minute features Alissa Willis, MD, of University of Mississippi Medical Center; and Merit Cudkowicz, MD, of Mass General Hospital and Harvard Medical School. [WATCH TIME: 4 minutes]
The consultant and founder of Accelerating NeuroVentures talked about the pridopidine arm from the HEALEY ALS Platform trial, which showed significant benefits in speech measures. [WATCH TIME: 5 minutes]
The director of vascular neurology at NYU Langone talked about how to identify the signs and symptoms of stroke and the importance of early intervention. [WATCH TIME: 4 minutes]
The senior academic at the University of Sydney provided perspective on the role of CNM-Au8 in MS among a crowded treatment landscape, and the need for adjuvant treatments that address lingering lesion burden. [WATCH TIME: 3 minutes]
The chief executive officer of Cognixion talked about the Cognixion ONE Axon, a wireless, wearable brain-computer interface that combines EEG technology with an augmented reality headset for patients with neurodegenerative diseases. [WATCH TIME: 4 minutes]
Neurology News Network for the week ending May 20, 2023. [WATCH TIME: 4 minutes]
